Development of a high efficiency dry powder inhaler: Effects of capsule chamber design and inhaler surface modifications

Pharmaceutical Research

Volumn 31, Issue 2, 2014, Pages 360-372

  Behara, Srinivas R B ^a,b   Farkas, Dale R ^a   Hindle, Michael ^b   Longest, P Worth ^a,b  

^a Virginia Commonwealth University   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

3D rod array; excipient enhanced growth; high efficiency DPI; low surface energy coatings; PTFE coating

Indexed keywords

EXCIPIENT; POLITEF;

AEROSOL; AIRFLOW; ARTICLE; DISPERSION; DRUG CAPSULE; DRUG RETENTION; DRY POWDER INHALER; FLUIDIZATION; PARTICLE SIZE; PRESSURE; PRIORITY JOURNAL;

AEROSOLS; CAPSULES; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EXCIPIENTS; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; POWDERS;

EID: 84896736547     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1165-6     Document Type: Article

References (41)

1. Islam N, Cleary MJ. Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery - a review for multidisciplinary researchers. Med Eng Phys. 2012;34:409-27.
2. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med. 2002;96:293-304.
3. Smith IJ, Bell J, Bowman N, Everard M, Stein S, Weers JG. Inhaler devices: what remains to be done? J Aerosol Med Pulm D. 2010;23:S25-37.
4. Brain JD, Blanchard JD. Mechanisms of particle deposition and clearance. In: More'n F, Dolovich MB, Newhouse MT, Newman SP, editors. Aerosols in medicine: principles, diagnosis and therapy. New York: Elsevier; 1993. p. 117-56.
5. DeHaan WH, Finlay WH. Predicting extrathoracic deposition from dry powder inhalers. J Aerosol Sci. 2004;35:309-31.
6. Delvadia R, Hindle M, Longest PW, Byron PR. In vitro tests for aerosol deposition. II: IVIVCs for different dry powder inhalers in normal adults. J Aerosol Med Pulm D. 2012;26:138-44.
7. Delvadia R, Longest PW, Byron PR. In vitro tests for aerosol deposition. I. Scaling a physical model of the upper airways to predict drug deposition variation in normal humans. J Aerosol Med Pulm D. 2012;25:32-40.
8. Zhang Y, Gilbertson K, Finlay WH. In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers. J Aerosol Med. 2007;20:227-35.
9. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of Tobramycin using PulmoSphereTM technology. J Aerosol Med Pulm D. 2011;24:175-82.
10. Weers JG, Bell J, Chan HK, Cipolla D, Dunbar C, Hickey AJ, et al. Pulmonary formulations: what remains to be done? J Aerosol Med Pulm D. 2010;23:S5-23.
11. Hindle M, Longest PW. Condensational growth of combination drug-excipient submicrometer particles for targeted high-efficiency pulmonary delivery: evaluation of formulation and delivery device. J Pharm Pharmacol. 2012;64:1254-63.
12. Longest PW, Tian G, Li X, Son Y-J, Hindle M. Performance of combination drug and hygroscopic excipient submicrometer particles from a softmist inhaler in a characteristic model of the airways. Ann Biomed Eng. 2012;40:2596-610.
13. Longest PW, Hindle M. Numerical model to characterize the size increase of combination drug and hygroscopic excipient nanoparticle aerosols. Aerosol Sci Technol. 2011;45:884-99.
14. Longest PW, Hindle M. Condensational growth of combination drug-excipient submicrometer particles: comparison of CFD predictions with experimental results. Pharm Res. 2012;29:707-21.
15. Tian G, Longest PW, Li X, Hindle M. Targeting aerosol deposition to and within the lung airways using excipient enhanced growth. J Aerosol Med Pulm D. 2013. doi: 10.1089/jamp.2012.0997.
16. Chan H-K. Dry powder aerosol delivery systems: current and future research directions. J Aerosol Med. 2006;19:21-7.
17. Chan H-K. Dry powder aerosol drug delivery - opportunities for colloid and surface scientists. Colloids Surf A. 2006;284-285:50-5.
18. Hickey AJ, Concession NM, Van Oort M, Platz M. Factors influencing the dispersion of dry powders as aerosols. Pharm Technol. 1994;8:58-82.
19. Son Y-J, Longest PW, Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. Int J Pharm. 2013;443:137-45.
20. Son Y-J, Longest PW, Hindle M. Evaluation and modification of commercial dry powder inhalers for the aerosolization of submicrometer excipient enhanced growth (EEG) formulation. Eur J Pharm Sci. 2013;49:390-9.
21. Longest PW, Son Y-J, Holbrook L, Hindle M. Aerodynamic factors responsible for the deaggregation of carrier-free drug powders to form micrometer and submicrometer aerosols. Pharm Res. 2013;30:1608-27.
22. Behara SRB, Kippax P, Larson I, Morton DAV, Stewart P. Kinetics of emitted mass - a study with three dry powder inhaler devices. Chem Eng Sci. 2011;66:5284-92.
23. Behara SRB, Larson I, Kippax P, Morton DAV, Stewart P. The kinetics of cohesive powder de-agglomeration from three inhaler devices. Int J Pharm. 2011;421:72-81.
24. Behara SRB, Larson I, Kippax P, Stewart P, Morton DAV. Insight into pressure drop dependent efficiencies of dry powder inhalers. Eur J Pharm Sci. 2012;46:142-8.
25. Podczeck F. Evaluation of the adhesion properties of salbutamol sulphate to inhaler materials. Pharm Res. 1998;15:806-8.
26. Selvam P, McNair D, Truman R, Smyth HD. A novel dry powder inhaler: effect of device design on dispersion performance. Int J Pharm. 2010;401:1-6.
27. Donovan MJ, Smyth HDC. Influence of size and surface roughness of large lactose carrier particles in dry powder inhlaer formulations. Int J Pharm. 2010;402:1-9.
28. Tuli RA, George GA, Dargaville TR, Islam N. Studies on the effect of the size of polycaprolactone microspheres for the dispersion of salbutamol sulfate from dry powder formulations. Pharm Res. 2012;29:2445-55.
29. Heng D, Lee SH, Ng WK, Chan H-K, Kwek JW, Tan RBH. Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization. Int J Pharm. 2013;452:194-200.
30. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing. J Aerosol Med. 1993;6:99-110.
31. Ganderton D, Byron PR. Harmonising inhaler testing across the pharmacopoeias. In: Dalby RN, Byron PR, Farr SJ, editors. RDD V. Pheonix: Interpharm Press; 1996. p. 283-92.
32. Hindle M, Jashnani RN, Byron PR. Dose emissions from marketed inhalers: influence of flow, volume and environment. In: Byron PR, Dalby RN, Farr SJ, editors. RDD IV. Richmond: Interpharm Press; 1994. p. 137-42.
33. Behara SRB, Kippax P, McIntosh MP, Morton DAV, Larson I, Stewart P. Structural influence of cohesive mixtures of salbutamol sulphate and lactose on aerosolisation and de-agglomeration behaviour under dynamic conditions. Eur J Pharm Sci. 2011;42:210-9.
34. Behara SRB, Larson I, Kippax P, Morton DAV, Stewart P. An approach to characterising the cohesive behaviour of powders using a flow titration aerosolisation based methodology. Chem Eng Sci. 2011;66:1640-8.
35. Wen HY, Kasper G. On the kinetics of particle reentrainment from surfaces. J Aerosol Sci. 1989;20:483-98.
36. Coates MS, Fletcher DF, Chan HK, Raper JA. The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res. 2005;22:923-32.
37. Shur J, Lee S, Adams W, Lionberger R, Tibbatts J, Price R. Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers. AAPS J. 2012;14:667-76.
38. Coates MS, Chan HK, Fletcher DF, Raper JA. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res. 2005;22:1445-53.
39. Voss A, Finlay WH. Deagglomeration of dry powder pharmaceutical aerosols. Int J Pharm. 2002;248:39-50.
40. Longest PW, Golshahi L, Hindle M. Improving pharmaceutical aerosol delivery during noninvasive ventilation: effects of streamlined components. Ann Biomed Eng. 2013;41:1217-32.
41. Lalor CB, Tepper JS, Froland WA. Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation. In PCT/US, editors; 2009; WO2009009775 A1.